Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
July 11, 2023 11:23 ET
|
Achieve Life Sciences
Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability” Supports potential for cytisinicline to be the first...
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
May 25, 2023 09:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
May 23, 2023 06:00 ET
|
Achieve Life Sciences
ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo ...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
April 24, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...